Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause by Sathyapalan, T.. et al.
Accepted Manuscript
Soy isoflavones improve cardiovascular disease risk markers in women during the
early menopause
Thozhukat Sathyapalan, Myint Aye, Alan S. Rigby, Natalie J. Thatcher, Soha R.
Dargham, Eric S. Kilpatrick, Stephen L. Atkin
PII: S0939-4753(18)30098-X
DOI: 10.1016/j.numecd.2018.03.007
Reference: NUMECD 1874
To appear in: Nutrition, Metabolism and Cardiovascular Diseases
Received Date: 20 November 2017
Revised Date: 13 March 2018
Accepted Date: 13 March 2018
Please cite this article as: Sathyapalan T, Aye M, Rigby AS, Thatcher NJ, Dargham SR, Kilpatrick
ES, Atkin SL, Soy isoflavones improve cardiovascular disease risk markers in women during
the early menopause, Nutrition, Metabolism and Cardiovascular Diseases (2018), doi: 10.1016/
j.numecd.2018.03.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
1 
 
Soy isoflavones improve cardiovascular disease risk markers in women during 1 
the early menopause 2 
1Thozhukat Sathyapalan, 1Myint Aye, 2Alan S Rigby, 3Natalie J Thatcher, 4Soha R 3 
Dargham, 5Eric S Kilpatrick, 4Stephen L Atkin 4 
1
 Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, 5 
University of Hull, Hull UK 6 
2
 Department of Academic Cardiology, University of Hull, UK  7 
3
 European Food Safety Authority, Parma, Italy 8 
4Weill Cornell Medical College Qatar, Education City PO Box 24144, Doha, Qatar 9 
5 Department of Clinical Chemistry, Sidra Medical and Research Center, PO Box 10 
26999, Doha, Qatar 11 
 12 
Corresponding author 13 
Dr SL Atkin, Weill Cornell Medical College Qatar, Education City, PO Box 24144,  14 
Doha, Qatar. 15 
Tel: +97455639807 16 
Fax +97444928422 17 
Email: sla2002@qatar-med.cornell.edu 18 
 19 
Word count 3656    Figures 1 20 
Tables  3    OSM 1 Figure 21 
Abbreviated title: Soy and cardiovascular disease risk. 22 
Conflict of interest 23 
 24 
No authors have any conflict of interest to declare 25 
 26 
Source of funding 27 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
2 
 
 This study was supported by the Food Standards Agency, United Kingdom (T01060).  28 
The sponsors did not influence the study design, collection, analysis, interpretation of 29 
data, writing of the report, or in the decision to submit the paper for publication 30 
 31 
Acknowledgement 32 
The phytoestrogen standards were produced as part of Food Standards Agency 33 
Contract T05001 and were donated for use in this project by Dr. Nigel P. Botting, 34 
Department of Chemistry, University of St. Andrews (St. Andrews, UK).  35 
Any views or opinions expressed are solely those of the authors and do not 36 
necessarily represent those of the FSA. 37 
 38 
Abbreviations. CVR = cardiovascular risk; SPI = soy with isoflavones; SP soy protein 39 
alone; CVD = cardiovascular disease; hsCRP= high sensitive C-reactive protein; CV= 40 
coefficient of variation; HDL= high density lipoprotein cholesterol; LDL= low 41 
density lipoprotein cholesterol; 42 
Keywords. Soy, isoflavones, cardiovascular risk, stroke, cardiovascular death, 43 
cardiovascular disease, postmenopausal   44 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
Abstract 45 
Background: Hormone replacement therapy may be beneficial for cardiovascular 46 
disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective 47 
estrogen receptor modulators. The aim of this study was to evaluate whether soy 48 
isoflavones had an effect on CVR markers.  49 
Methods: The expected 10-year risk of cardiovascular disease and mortality were 50 
calculated as a secondary endpoint from a double blind randomised parallel study 51 
involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early 52 
menopause who were randomised to 15g soy protein with 66mg isoflavone (SPI) or 53 
15g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between 54 
meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles 55 
were used to calculate CVR using the Framingham CVR engine.  56 
Results: SPI treatment resulted in a significant reduction in the metabolic parameters 57 
and systolic blood pressure compared to SP  (p<0.01).  There were no changes in 58 
fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, 59 
changes in these parameters with SPI treatment were reflected in a calculated 27% 60 
(p<0.01) reduction in 10 year coronary heart disease risk, a 37% (p<0.01) reduction in 61 
myocardial infarction risk, a 24% (p<0.04) reduction in cardiovascular disease and 62 
42% (p<0.02) reduction in cardiovascular disease death risk.  63 
Conclusions: Supplementation with soy protein with isoflavones for 6 months 64 
significantly improved CVR markers and calculated CVR at 6 months during early 65 
menopause compared to soy protein without isoflavones.  66 
ISRCTN registry – ISRCTN34051237 67 
  68 
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Introduction 69 
Cardiovascular disease (CVD) is uncommon in premenopausal women, but at the 70 
menopause there is an increased and recognised cardiovascular disease risk (CVR) for 71 
coronary heart disease (CHD) (1). Analysis of the Women’s Health Initiative study 72 
suggested that women treated with hormone replacement therapy (HRT) did not have 73 
an increased risk of CHD and indeed it may result in reduced CVR if estrogen was 74 
given within 10 years of their menopause compared to those who were not on HRT 75 
(2). Soy isoflavones can act as selective estrogen receptor modulators that may have 76 
beneficial effects on CVR indices (3, 4). Although there are studies comparing the 77 
effect of whole soy, soy protein and isoflavones showing variable effect on 78 
cardiovascular disease risk markers (5-8), there are no studies looking into the effect 79 
of combined soy protein and isoflavones with isoflavone free comparator in post-80 
menopausal women.   81 
The isoflavones are heterocyclic phenols that mainly comprise genistein, daidzein and 82 
glycitein that have both in vitro and in vivo estrogenic effects due to their structure 83 
that is similar in structure to 17 beta estradiol (3).  Equol is produced by the 84 
metabolism of the isoflavone daidzein by intestinal bacteria. In Western countries, 85 
30% to 50% of individuals metabolize daidzein into equol and are known as equol 86 
producers. It has been suggested that equol production may be the source of benefit 87 
from isoflavones(9).  Isoflavones can potentially improve cardiovascular health by 88 
maintaining endothelial integrity and increase nitric oxide, prostacyclin release 89 
leading to endothelium-dependent vasodilation (10). Isoflavones can also inhibit 90 
vascular smooth muscle proliferation and contraction by activating cAMP- and 91 
cGMP-dependent pathways and decreasing Ca2+ influx and release (10). Isoflavones 92 
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have also been shown to reduce oxidative stress, inhibit angiogenesis and attenuate 93 
vascular inflammation (10). 94 
 95 
The Framingham Risk Score is an algorithm commonly used to estimate the 10-year 96 
cardiovascular risk of an individual without diabetes inputting various variables 97 
including age, sex, smoking status, total cholesterol, LDL-cholesterol, systolic blood 98 
pressure and use of anti-hypertensive medications (11). This has been used in 99 
prospective studies to assess the cardiovascular risk (12). We have previously shown 100 
a reduction in cardiovascular disease risk markers using this soy/isoflavone 101 
preparation in men (4). Therefore, a post hoc analysis of cardiovascular risk using the 102 
Framingham Risk Score was undertaken in this randomised, double blind, parallel 103 
study in which the primary end point was a change in bone turnover markers (13). 104 
Materials and methods 105 
Two hundred Caucasian women from the Hull and East Riding of Yorkshire, UK 106 
within two years of the onset of their menopause (FSH greater than 20 mU/L and 107 
amenorrhoea for one year) were recruited after screening 334 women who responded 108 
to newspaper advertisements (13). None of the patients were taking any prescription 109 
or over the counter medications. Women with a previous history of medication that 110 
could interfere with bone metabolism including steroids, bisphosphonates, thyroxine 111 
or hormone replacement therapy were excluded. All women were non-smokers and no 112 
subject had type 2 diabetes. Women with significant hepatic or renal impairment, who 113 
were allergic to soy products and those who had antibiotic exposure in the three 114 
months prior to the study, were also excluded. The study was undertaken at the 115 
Diabetes, Endocrinology and Metabolism centre, Hull Royal Infirmary, UK. 116 
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Two hundred women were randomised into either the SPI group (15 g soy protein 117 
with 66 mg of isoflavones) or SP group (15 g soy protein alone, isoflavone free) daily 118 
for a period of six months, administered as below.   119 
The primary outcome of this study was to assess the plasma bone turnover markers 120 
(13). The secondary outcomes for this study were the assessment of cardiovascular 121 
disease risk markers including insulin resistance, lipids, and hsCRP, but their 122 
assessment within the Framingham risk engine was a new analysis within this dataset.  123 
During study visits (baseline, three months and six months), participants were 124 
instructed to maintain their normal level of physical activity throughout the study. In 125 
addition, participants were required to avoid food products containing soy, alcohol, 126 
vitamin or mineral supplementation, and over-the-counter medications. No other 127 
changes in the diet were recommended. Dietary reinforcement was undertaken at each 128 
visit by a registered dietician, together with measurement of serum isoflavone 129 
concentrations to ensure compliance. There was telephone contact by study personnel, 130 
six and 18 weeks after study visits to ensure compliance. Analysis of compliance with 131 
the study preparation was undertaken by counting the returned sachets. All 132 
participants gave their written informed consent for this study that had been approved 133 
by the Research Ethics Committee (East Yorkshire & North Lincolnshire Research 134 
Ethics Committee, ref: 09/1304/45).    135 
Study product 136 
The intervention comprised a snack bar containing 7.5 g isolated soy protein powder 137 
(Solcon F, Solbar Industries, Israel) with 33 mg of isoflavones (SPI) (Solgen 40, 138 
Solbar Industries, Ashdod, Israel) given twice daily between meals (15 g soy protein 139 
and 66 mg of isoflavones per day), or 7.5 g of the isolated soy protein alone given 140 
twice daily (15 g soy protein per day without isoflavones per day) as control (SP). The 141 
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latter had an isoflavone concentration of less than 300 parts per billion following 142 
serial alcohol extraction by Dishman Ltd, India(13); and product isoflavones assayed 143 
by FERA, Sand Hutton, UK(13). Analysis showed the composition of the dose 144 
materials to be 54% genistein, 35% daidzein, and 12% glycitein as aglycones and 145 
further confirmed that 90% of phytoestrogens were in the primary glucoside form, 146 
with the remaining 10% as aglycones or acetyl and malonyl glucosides. The soy with 147 
and without isoflavones was analysed using AOCS official method Ba 4d-90 148 
“Nitrogen-ammonia-protein modified Kjeldahl method titanium dioxide + copper 149 
sulphate catalyst” that determines total nitrogen content and protein. The snack bars 150 
were eaten twice daily between meals for 6 months. The soy protein and the 151 
isoflavones were from a single batch that was designated for the study. The study bars 152 
were specifically commissioned, prepared (soy with and without isoflavones, mixed 153 
with water and cold compressed into a snack bar) and packaged by Halo foods, 154 
Swindon, UK. Soy bars of similar macronutrient content were identical in size, shape, 155 
texture and both arms were in identical packaging; a taste panel prior to the study 156 
could not distinguish a difference in taste between the 2 preparations. There was no 157 
difference in side effects or drop outs that would distinguish between the 2 products. 158 
 159 
Randomisation 160 
The randomisation was performed by Essential Nutrition Ltd, UK as detailed(13), 161 
using a computer generated randomisation sequence was used to provide balanced 162 
blocks of patient numbers for each of the two treatment groups. Compliance was 163 
documented by return of the empty wrappers and uneaten bars. 164 
Study measurements 165 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
8 
 
During the baseline, three months and six month study visits, and following an over-166 
night fast, anthropometric parameters were measured and blood samples collected, 167 
stored at -80oC and insulin batch analysed at the end of the study. Blood pressure was 168 
measured after the participants had been seated quietly for at least five minutes with 169 
the right arm supported at heart level. Blood pressure measurements were performed 170 
using an automated device (NPB-3900; Nellcor Puritan Bennett, Pleasanton, CA) 171 
during each study visit. Two readings were obtained at the beginning of each visit at 172 
least one minute apart and the average of the readings was taken. Fasting venous 173 
blood samples were collected and prepared as previously described (13). Briefly, 174 
blood was separated by centrifugation at 2000 g for 15 min at 4oC, and the aliquots 175 
stored at -80oC within one hour of collection. Plasma glucose was measured using a 176 
Synchron DxC analyzer (Beckman-Coulter, UK), and serum insulin was assayed 177 
using an ultra-sensitive chemiluminescent one-step immunoenzymetic ‘sandwich’ 178 
assay performed on a Unicel DXi Immunoassay system (Beckman-Coulter, UK). The 179 
coefficient of variation (CV) of this method was 8%, calculated using duplicate study 180 
samples. The analytical sensitivity was 2 µU/mL.  Insulin resistance was calculated 181 
using HOMA-IR (Insulin x glucose)/22.5) (14).  182 
Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL) levels 183 
were measured enzymatically using a Synchron DxC analyzer (Beckman-Coulter, 184 
UK). Low-density lipoprotein cholesterol (LDL) was calculated using the Friedewald 185 
equation. At a mean total cholesterol of 4.9mmol/l combined within and between 186 
(intralab) CV was 0.7%; at a mean HDL of 0.9mmol/l combined within and between 187 
CV was 1.0%; at a mean triglyceride level of 1.61mmol/l combined within and 188 
between CV was 0.94%; at a mean hsCRP of 8.4mmol/l combined within and 189 
between CV was 1.1%). 190 
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The isoflavones in serum were extracted and analysed by LGC, Fordham, 191 
Cambridgeshire, UK using isotope-dilution LC-MS/MS (15). LC-MS/MS was 192 
conducted using a Sciex 4000 Qtrap with separation achieved using a C18 column 193 
and mobile phases of water and acetonitrile, both containing acetic acid(16). 194 
The calculated risk scores between groups using the Framingham equation (11) 195 
(based on age, total cholesterol, HDL and systolic blood pressure: smoking and 196 
diabetes were exclusion criteria in this study and therefore set to zero in the 197 
calculation) were performed at 6 months as this was the pre-determined end point of 198 
the study 199 
Statistical analysis 200 
Sample size was powered for changes in bone markers and not specifically for 201 
cardiovascular risk (13): a post hoc power analysis for CVR would have been poor 202 
statistical practice and as such was not conducted. An intention to treat analysis was 203 
undertaken; however, the data from withdrawals were included as part of intention-to-204 
treat analysis. Baseline values were not compared statistically given that this was a 205 
randomised controlled trial. For each group (SPI and SP) separately a paired 206 
difference (six-months minus baseline) of means was calculated, the two paired 207 
means were then compared using an independent t-test; the p-value is the probability 208 
of the difference of the difference being a false positive. This is referred to in 209 
supplementary Table 1 as the 'difference of the difference' and 95% confidence 210 
interval gives the precision of the difference of the difference in the tables. This 211 
difference of the difference at 6 months is shown in Supplementary Table 2 for the 212 
metabolic factors as well as in Table 1 for the calculated cardiovascular risk. A paired 213 
t test for baseline to 3 months and 3 months to six-months within groups was 214 
performed for the metabolic factors and cardiovascular risk to assess trend. Data was 215 
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analysed using the Stata statistical computer package (StataCorp. Stata Statistical 216 
Software.  Release 13. College Station, Texas, 2013).  217 
  218 
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Results 219 
120 women completed six months of the study, 60 in the SPI group and 60 in the SP 220 
group with an overall dropout rate of 40%: the main reasons for dropping out of the 221 
study are detailed in supplementary Figure 1 (13).  222 
The baseline anthropometric, metabolic, plasma isoflavone levels were comparable 223 
between the two groups and may be seen in Table 1.  224 
Serum Diadzein, genistein and equol were increased in the SPI group confirming 225 
compliance (p<0.001) whilst those in the SP group did not differ between baseline, 3 226 
months and 6 months; bone marker concentrations changed significantly during the 227 
study as described elsewhere (13).  Empty wrappers and uneaten bars were returned 228 
and counted by the study team. If compliance was less than 75% then the subject was 229 
to be withdrawn from the study: those that completed the study had a compliance of 230 
more than 90%. 231 
Changes in the metabolic parameters after 6 months are shown in Table 2 with 232 
decreased fasting glucose, fasting insulin and HOMA-IR. Lipid parameters (total 233 
cholesterol, LDL, HDL and triglycerides) and hsCRP were unchanged between 234 
treatment groups. There was a significant reduction in systolic blood pressure at six 235 
months between SP and SPI supplementation though diastolic blood pressure was 236 
unchanged.  (Table 2). 237 
There was no difference in the baseline characteristics of those that dropped out of the 238 
study versus those that completed the study.  239 
 240 
The within group calculation risk at 3 months, and 3 months to 6 months was 241 
performed to determine trend across the time period and is shown in Figure 1. The 242 
calculated 10 year risk for coronary heart disease showed a 27% reduction at 6 243 
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months comparing SPI with SP (p<0.01), though only the within group change for 244 
SPI, but not SP, showed a significant reduction at 3 months and a subsequent further 245 
reduction at 6 months. The calculated 10 year myocardial infarction risk showed a 246 
37% reduction at 6 months between SPI and SP (p<0.01); the within group change for 247 
SPI, but not SP, showed a significant reduction at 3 months and a subsequent further 248 
reduction at 6 months. The calculated 10 year cardiovascular disease risk showed a 249 
24% reduction at 6 months between SPI and SP (p<0.04); the within group change for 250 
SPI, but not SP, showed a significant reduction at 3 months and a subsequent further 251 
reduction at 6 months. The calculated 10 year cardiovascular death risk showed a 42% 252 
reduction at 6 months between SPI and SP (p<0.02); the within group change for SPI, 253 
but not SP, showed a significant reduction at 3 months and a subsequent further 254 
reduction at 6 months (Figure 1). Stroke and death from coronary heart disease did 255 
not differ at 6 months between SP and SPI treatment (Figure 1); however, it is of 256 
interest that risk of stroke decreased within groups for both the SPI and SP groups.  257 
No one isoflavone measured (genistein, diadzein, equol) in the SPI group showed a 258 
difference in Framingham score compared to each other (p>0.05), and there was no 259 
difference between equol producers (n=38) and equol non-producers (n=22) for 260 
cardiovascular risk (data not shown). The prevalence of equol producers was 19% in 261 
this study which is comparable to that seen in the Caucasian population (9). 262 
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Discussion 263 
The calculation of the CVR parameters showed a significant reduction in calculated 264 
10-year coronary heart disease (27%), myocardial infarction (37%), cardiovascular 265 
risk (24%) and death due to cardiovascular disease (42%) with SPI supplementation 266 
using the Framingham equation (11, 17). This is in accord with an observational study 267 
using dietary recall where high isoflavone intake was associated with reduced risk of 268 
cerebral and myocardial infarction that was more pronounced for postmenopausal 269 
women (5, 18). A Japanese study of the traditional soy food natto showed a decrease 270 
in CVD mortality(6). Others have shown that soy protein along with isoflavone 271 
supplementation may reduce subclinical atherosclerosis in women at low-risk for 272 
cardiovascular disease who were <5 years postmenopausal (7). The effect of the 273 
soy/isoflavones SPI preparation on CVR parameters and indices reflects those seen in 274 
a study using the same preparation in hypogondal men with type 2 diabetes (4). 275 
Stroke risk did not differ at 6 months between SP and SPI treatment; however, it is of 276 
interest that risk of stroke decreased within groups for both the SPI and SP groups. 277 
The risk of cerebral infarction has been noted to decrease with soy intake, particularly 278 
in postmenopausal women (18) and in the natto study, a decrease of stroke was only 279 
seen at the highest quartiles of soy intake, above that of this study(6). A meta-analysis 280 
of eleven trials demonstrated that soy isoflavone intake resulted in a mean decrease of 281 
2.5 mmHg for systolic blood pressure compared to placebo (19); however, there was 282 
significant heterogeneity between the studies. A 4–5 mmHg reduction in systolic 283 
blood pressure can reduce CVD risk by 8–20% (20). In the current study, there was a 284 
3.2mmHg reduction in systolic blood pressure with soy protein and isoflavone 285 
supplementation for 6 months. An improvement in systolic pressure alone was seen in 286 
a study using the same isoflavone preparation with soy protein as here(21), but in a 287 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
14 
 
study in type 2 diabetes  patients treated with 132mg tablets of isoflavone alone 288 
without soy protein there was no effect on systolic blood pressure (5).   This suggests 289 
that a synergistic matrix effect between the soy protein with the isoflavones may be 290 
responsible for any cardiovascular disease changes since both supplements contains 291 
the same amount of protein.   292 
Given that this was a healthy volunteer population without other cardiovascular 293 
comorbidities and therefore were not likely to have had any additional cardiovascular 294 
risk; thus repeating this study in a population of greater risk may likely see increased 295 
benefits. There were no significant changes for body mass index, diastolic blood 296 
pressure, hsCRP and lipid profile, and the reduction in predicted 10-year 297 
cardiovascular disease risk from the Framingham risk score that was derived from the 298 
decreased systolic blood pressure. 299 
There was a significant reduction in systolic blood pressure with three months of SPI 300 
that did not improve further at 6 months, but no changes were seen with SP, and 301 
diastolic blood pressure remained unchanged with treatment. Participants’ age and 302 
systolic blood pressure are the two most potent risk factors included in the 303 
Framingham risk equation, so although lipids were no different between the groups, 304 
presumably the overall cardiovascular risk calculation was being driven by the 305 
observed SBP difference. 306 
There were no changes in the total cholesterol, LDL, HDL or triglyceride levels by 307 
the soy preparations between groups at 6 months, results that are in accord with others 308 
where the placebo used was cellulose (5) and lipid parameters were unchanged. This 309 
is the converse reported for a soy with a cassein comparator study that reported a 4% 310 
reduction in LDL (22). Reductions in both total cholesterol and LDL, but not HDL 311 
were detailed in a meta-analysis (23), though differences in study design and small 312 
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study numbers, soy preparation, isoflavone composition (glucoside or aglycone 313 
forms) would all contribute to the discrepant findings here and in other studies. 314 
However, 15g/day of soy were used in this study that may have been too little to 315 
reduce cholesterol, thought to be due to the soy protein affect, and a Food and Drug 316 
Administration claim called for 25g/ day to be effective. There were no differences in 317 
the cardiovascular risk parameters between producers and non-producers of equol in 318 
accord with the 28 negative studies reported in a recent meta-analysis (24). It is not 319 
known whether these cardiovascular beneficial effects would continue in the future 320 
with the cessation of soy treatment, akin to the metabolic memory seen in diabetes 321 
(25),  or would be short term with only an effect whilst taking the soy preparation.  322 
Dietary intake of isoflavones in Asian soy diets has been estimated to be in the range 323 
of 30-50 mg per day of combined isoflavone aglycone equivalents(26, 27). In Western 324 
countries an average daily intake of approximately 2 mg isoflavones is seen though 325 
estimated to be 16mg in vegetarians(28); therefore, the dose of 66mg of isoflavones 326 
used in this study may be considered to be in the pharmacological range. 327 
The strength of this study is that this study is unique in using a soy preparation well 328 
defined from a single batch that was truly isoflavone free that could determine the 329 
contribution to any cardiovascular disease risk effect by the soy protein alone.  No 330 
treatment effects on the individual parameters were seen for soy protein alone, 331 
suggesting that the soy protein by itself is inactive. Whilst there was no difference in 332 
the protein composition between soy with and without isoflavones following serial 333 
alcohol washing, the serial alcohol washing could have altered the tertiary structure of 334 
the protein and removed other components besides isoflavones. The limitations of this 335 
study include that the cardiovascular disease risk markers were not the primary aim of 336 
the study. However, the study was over powered for the primary outcome and 337 
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analysed as an intention to treat thus minimizing the anticipated dropout rate. The 338 
dropout was around 40% as anticipated so that the power of the study was not 339 
compromised. This approach circumvented the concerns of a potential type 2 error for 340 
the primary variable. Furthermore, the changes in the CVR markers were in accord 341 
with another large study using the same preparation (4). The features of those that 342 
dropped of the study did not differ between groups nor differed to those that 343 
completed. Plasma isoflavone concentrations increased in the SPI alone confirming 344 
compliance, whilst the SP group did not change from baseline excluding exogenous 345 
isoflavone ingestion.  Whilst dietary advice was given at each visit, formal dietary 346 
assessment to determine macronutrient intake was not undertaken so it is possible that 347 
the ingestion of the extra 15g of soy protein may have subtly altered dietary habits 348 
that may have contributed to the results. 349 
In conclusion, there was a beneficial effect on systolic blood pressure with soy and 350 
isoflavone intake over 6 months in this population of women in their early 351 
menopause, and the reduction in systolic blood pressure was reflected in 352 
cardiovascular disease risk calculated by the Framingham equation.  353 
  354 
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Legend to Figure 1 462 
Trend in cardiovascular disease risk reduction with soy protein and isoflavone (SPI) 463 
and soy protein alone (SP) showing the within group changes from baseline to 3 464 
months and from 3 months to 6 months using Framingham criteria. Data show the 465 
progressive fall in the risk parameter over the 6 month period of the study for the SPI 466 
treated group for A), CHD; B), CHD death; D,  MI; E), CVD; F), CVD death, but not 467 
for C), stroke. 468 
CHD – 10 year coronary heart disease risk. MI – 10 year myocardial infarction risk. 469 
Stroke – 10 year stroke risk. CVD – 10 year cardiovascular risk. CHD death – 10 year 470 
risk for death due to coronary heart disease. CVD death – 10 year risk for death due to 471 
cardiovascular disease. Error bars are SEM. 472 
 473 
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Table 1. Baseline anthropometric, hormonal and biochemical measurements 
between the soy protein with (SPI) and without (SP) isoflavones.  
 
Parameters SPI (n=100) SP (n=100) 
Age (years) 52 (49, 56) 52 (50, 55) 
Body mass index (kg/m2) 26.3 (24.3, 30.7) 24.6 (22.7, 28.4) 
Systolic blood pressure (mmHg) 121 (110, 137) 128 (113, 141) 
Diastolic blood pressure (mmHg) 77 (69, 88) 79 (72, 83) 
aFasting glucose (mg/dL) 90 (86.4, 99.0) 86.4 (82.8, 93.6) 
bFasting insulin (µIU/mL) 4.6 (3.4, 6.7) 4.4 (3.2, 7.4) 
HOMA-IR 1.0 (0.7, 1.5) 0.9 (0.7, 1.6) 
hs CRP (mg/L) 1.3 (0.6, 2.2) 1.3 (0.9, 2.7) 
cTC (mmol/L) 5.98 (5.38, 6.54) 5.66 (4.98, 6.37) 
LDL-C (mmol/L) 3.3 (2.9, 3.9) 3.3 (2.7, 3.9) 
HDL-C (mmol/L) 1.66 (1.45, 1.88) 1.70 (1.46, 2.10) 
dTriglycerides (mmol/L) 1.08 (0.85, 1.36) 1.08 (0.84, 1.33) 
Daidzein (ng/mL) 0.73 (0.49, 2.37) 0.82 (0.49, 2.65) 
Genistin (ng/mL) 1.43 (0.56, 4.2) 1.66 (0.71, 6.98) 
Equol (ng/mL) 0.49 (0.47, 0.51) 0.49 (0.46, 0.54) 
FSH (IU/L) 77 (57, 97) 71 (49, 89) 
LH (IU/L) 32 (25, 42) 29 (27, 38) 
 
SPI (15 g soy protein with 66 mg of isoflavones); SP (15 g soy protein alone isoflavone free) 
Data given as Mean (SEM). aTo convert values for glucose to milligrams per deciliter, divide by 0.056.  
bTo convert values for insulin to picomoles per liter, multiply by 6. cTo convert values for cholesterol to 
milligrams per deciliter, divide by 0.0259. dTo convert values for triglycerides to milligrams per 
deciliter, divide by 0.0113. TC - Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL 
cholesterol; TG-Triglycerides. HOMA-IR – Homeostasis model of assessment – insulin resistance. 
hs CRP – highly sensitive C-reactive protein. FSH – follicle stimulating hormone, LH – Luteinising 
hormone 
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Table 2. Comparison between SPI (n=60) and SP (n=60) supplementation at end of 
study of metabolic and hormonal factors.   
Parameter 
SPI SP Difference 
of the 
difference 
(95% CI) 
p-
value 
Baseline 
Mean 
(SD) 
6 
months 
Mean 
(SD) 
Difference 
(6 mo – 
baseline) 
Baseline 
Mean 
(SD) 
6 
months 
Mean 
(SD) 
Difference 
(6 mo – 
baseline) 
Body mass 
index  
(kg/m2) 
27 (4.6) 27.3 (4.4) 0.37 
26.7 
(7.0) 27 (6.9) 0.15 
0.2 (-
0.09,0.53) 0.17 
Systolic 
blood 
pressure 
(mmHg) 
125 
(20.2) 
121.2 
(14.9) -3.2 
124.6 
(18.8) 
123.4 
(16) -0.8 
-2.5 (-4.2,-
1.9) <0.01 
Diastolic 
blood 
pressure 
(mmHg) 
77 (13.8) 76.8 (9.4) -0.6 
77.2 
(10.9) 
77.4 
(11.6) 0.2 
-0.8 (-
5.2,3.4) 0.68 
TC  
(mmol/L) 5.8 (0.9) 5.8 (0.9) 0 5.8 (0.8) 5.7 (0.8) -0.15 
0.2 (-
0.07,0.47) 0.15 
LDL-C  
(mmol/L) 
3.65 
(0.7) 3.6 (0.6) -0.15 
3.65 
(0.9) 
3.57 
(0.75) -0.10 
-0.16 (-
0.65,0.72) 0.47 
HDL-C  
(mmol/L) 
1.68 
(0.94) 
1.62 
(0.36) -0.05 
1.78 
(0.42) 
1.65 
(0.39) -0.23 
-0.37 (-
1.28,0.52) 0.39 
Triglycerides  
(mmol/L) 
1.16 
(0.54) 
1.22 
(0.71) 0.09 
1.18 
(0.57) 
1.27 
(0.91) 0.09 
-0.12 (-
0.31,0.06) 0.20 
hs CRP  
(mg/L) 
1.65 
(1.55) 
0.69 
(0.92) -0.96 
2.65 
(4.49) 
2.1 
(2.27) -0.5 
-0.46 (-
1.6,0.58) 0.38 
Fasting 
glucose  
(mmol/L) 
5.2 (0.7) 4.4 (0.5) -0.7 5.1 (1.6) 5.0 (0.9) -0.10 -0.7 (-1,-0.4) <0.01 
Fasting 
insulin  
(µIU/mL) 
5.78 
(3.59) 
2.64 
(1.89) -3.1 
5.65 
(3.74) 
5.82 
(3.7) 0.11 
-3.25 (-4.-
2.43) <0.01 
HOMA-IR 1.39 (1.03) 
0.52 
(0.4) -0.86 
1.43 
(1.77) 
1.37 
(1.42) -0.04 
-0.82 (-
1.07,-0.56) <0.01 
Paired difference=6-months-baseline.  Difference of the difference is an unpaired t-test of the 
paired differences. SPI (15g soy protein with 66mg of isoflavones); SP (15g soy protein alone 
isoflavone free). HOMA-IR – Homeostasis model of assessment – insulin resistance; TC - 
Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL cholesterol; TG-Triglycerides; 
hs CRP – highly sensitive C reactive protein 
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Highlights 
• Cardiovascular risk indices were reduced in postmenopausal women 
treated with soy and isoflavones 
• There was a 27% reduction in 10 year coronary heart disease risk 
• There was a 37% reduction in myocardial infarction risk 
• There was a 24% (p<0.04) reduction in cardiovascular disease  
• There was a 42% reduction in cardiovascular disease death risk.  
 
